Arno Therapeutics (ARNI) Stock Price, News & Analysis

Company Overview

Arno Therapeutics, Inc. (OTCMKTS:ARNI) is a development‐stage biopharmaceutical company focused on the research and development of targeted therapeutics for oncology indications and rare genetic disorders. The company’s mission is to apply innovative biologic and protein engineering platforms to create therapies that address significant unmet medical needs in cancer and inherited metabolic conditions.

Arno’s pipeline centers on antibody‐based drug conjugates and recombinant fusion proteins designed to selectively target tumor cells or restore deficient enzyme activity in rare diseases. Although its programs remain in preclinical and early development stages, the company has secured intellectual property rights and in‐licensed technologies to advance multiple candidates toward Investigational New Drug (IND) filings.

To bolster its research efforts, Arno Therapeutics has entered into collaboration and licensing agreements with academic institutions and specialized biotechnology firms. These partnerships grant access to novel targeting platforms, enhance preclinical data generation and support scale‐up activities in anticipation of future clinical trials. The company aims to leverage these relationships to accelerate development timelines and de‐risk its lead programs.

Headquartered in Delray Beach, Florida, Arno Therapeutics is led by a management team with experience in biopharmaceutical development, clinical operations and regulatory affairs. The company continues to build its organizational capabilities, with the goal of advancing its pipeline and establishing a presence in U.S. and select international markets upon achieving clinical milestones.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 8,820 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:ARNI
• CIK: 1195116
• Web: www.arnothera.com
• Phone: (503) 598-6659
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A